UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 15, 2005
(Exact name of registrant as specified in its charter)
MASSACHUSETTS |
|
000-19319 |
|
04-3039129 |
(State or other jurisdiction of |
|
(Commission File Number) |
|
(IRS Employer Identification |
130 Waverly Street
Cambridge, Massachusetts 02139
(Address of principal executive offices) (Zip Code)
(617) 444-6100
Registrants telephone number, including area code:
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events.
On June 15, 2005, Vertex Pharmaceuticals Incorporated issued a press release that announced that the underwriters in the companys public offering exercised their over-allotment option to purchase 1,762,500 shares of common stock. A copy of that press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
VERTEX PHARMACEUTICALS |
|
|
|
INCORPORATED |
|
|
|
(Registrant) |
|
|
|
|
|
|
Date: June 15, 2005 |
/s/ Kenneth S. Boger |
|
|
|
Kenneth S. Boger |
|
|
|
Senior Vice President and General Counsel |
|
|
2
Exhibit 99.1
FOR IMMEDIATE RELEASE
Cambridge, MA, June 15, 2005 Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the underwriters have exercised in full their over-allotment option to purchase 1,762,500 shares of common stock at a public offering price of $13.00 per share. Upon the closing of the purchase of the over-allotment shares, a total of 13,512,500 shares of common stock will have been sold in the offering by Vertex, resulting in gross proceeds, before commissions and expenses, of $175.7 million.
Merrill Lynch, Pierce, Fenner & Smith Incorporated acted as the sole book-running manager in this offering. J.P. Morgan Securities Inc. and UBS Securities LLC acted as co-managers.
-more-
Vertex Pharmaceuticals Incorporated is a global biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases. The Companys strategy is to commercialize its products both independently and in collaboration with major pharmaceutical companies. Vertexs product pipeline is principally focused on viral diseases, inflammation, autoimmune diseases and cancer. Vertex co-promotes the HIV protease inhibitor, Lexiva®, with GlaxoSmithKline.
Lexiva® is a registered trademark of the GlaxoSmithKline group of companies.
Vertexs press releases are available at www.vrtx.com
###
Vertex Contacts:
Lynne H. Brum, VP, Corporate Communications and Financial Planning, (617) 444-6614
Michael Partridge, Director, Corporate Communications, (617) 444-6108
Lora Pike, Manager, Investor Relations, (617) 444-6755
2